SAN DIEGO, Oct. 7 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced that it will host a meeting for analysts and investors on October 14, 2010 in New York. During the meeting, Halozyme's management will present a review of its proprietary product development pipeline, business alliances with Roche and Baxter, and an update on other aspects of its business strategy.
(Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)
(Logo: http://www.newscom.com/cgi-bin/prnh/20100302/LA63139LOGO)
Presenters at the meeting will include Jonathan Lim, M.D., president and CEO, Gregory I. Frost, Ph.D., chief scientific officer, Kurt Gustafson, chief financial officer, Robert Little, chief commercial officer, and Doug Muchmore, M.D., vice president, endocrinology clinical development.
Halozyme will conduct a live webcast of the presentations beginning at approximately 12:15 p.m. EDT. To access the webcast over the Internet, please go to the company Web site at www.halozyme.com. An archive of the presentation will be available on Halozyme's Web site shortly after the conclusion of the meeting.
About Halozyme
Halozyme Therapeutics is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets. The company's product portfolio is based primarily on intellectual property covering the family of human enzymes known as hyaluronidases and additional enzymes that affect the extracellular matrix. Halozyme's Enhanze™ technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. The company has key partnerships with Roche to apply Enhanze technology to Roche's biological therapeutics, including Herceptin® and MabThera®, for up to 13 targets, and with Baxter BioScience to apply Enhanze technology to GAMMAGARD Liquid®. Halozyme's Ultrafast Insulin program combines its rHuPH20 enzyme with mealtime insulins, which may produce more rapid absorption, faster action, and improved glycemic control. The product candidates in Halozyme's pipeline target multiple areas of significant unmet medical need. For more information visit www.halozyme.com.
SOURCE Halozyme Therapeutics, Inc.